Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Resveratrol and inflammation : challenges in translating pre-clinical findings to improved patient outcomes. / Poulsen, Morten Møller; Fjeldborg, Karen; Ornstrup, Marie Juul; Kjær, Thomas Nordstrøm; Nøhr, Mark Klitgaard; Pedersen, Steen Bønløkke.
I: B B A - Molecular Basis of Disease, Bind 1852, Nr. 6, 2015, s. 1124-1136.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Resveratrol and inflammation
T2 - challenges in translating pre-clinical findings to improved patient outcomes
AU - Poulsen, Morten Møller
AU - Fjeldborg, Karen
AU - Ornstrup, Marie Juul
AU - Kjær, Thomas Nordstrøm
AU - Nøhr, Mark Klitgaard
AU - Pedersen, Steen Bønløkke
N1 - Copyright © 2015 Elsevier B.V. All rights reserved.
PY - 2015
Y1 - 2015
N2 - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.
AB - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.
KW - Adipose Tissue/drug effects
KW - Animals
KW - Anti-Inflammatory Agents, Non-Steroidal/pharmacology
KW - Clinical Trials as Topic
KW - Humans
KW - Inflammation/drug therapy
KW - Obesity/drug therapy
KW - Stilbenes/pharmacology
KW - Translational Medical Research
U2 - 10.1016/j.bbadis.2014.12.024
DO - 10.1016/j.bbadis.2014.12.024
M3 - Review
C2 - 25583116
VL - 1852
SP - 1124
EP - 1136
JO - B B A - Molecular Basis of Disease
JF - B B A - Molecular Basis of Disease
SN - 0925-4439
IS - 6
ER -
ID: 195591641